Morgan Stanley’s Cocrystal Pharma COCP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $915 | Sell |
871
-77
| -8% | -$95 | ﹤0.01% | 7524 |
|
|
2026
Q1 | $957 | Hold |
948
| – | – | ﹤0.01% | 7440 |
|
|
2025
Q4 | $928 | Sell |
948
-4,915
| -84% | -$5.2K | ﹤0.01% | 7385 |
|
|
2025
Q3 | $7.33K | Hold |
5,863
| – | – | ﹤0.01% | 6987 |
|
|
2025
Q2 | $8.74K | Hold |
5,863
| – | – | ﹤0.01% | 6895 |
|
|
2025
Q1 | $8.33K | Sell |
5,863
-58,483
| -91% | -$109K | ﹤0.01% | 6851 |
|
|
2024
Q4 | $130K | Buy |
64,346
+5,046
| +9% | +$10.1K | ﹤0.01% | 5952 |
|
|
2024
Q3 | $104K | Hold |
59,300
| – | – | ﹤0.01% | 5991 |
|
|
2024
Q2 | $138K | Buy |
59,300
+29
| +0% | +$57 | ﹤0.01% | 5839 |
|
|
2024
Q1 | $83K | Sell |
59,271
-6
| -0% | -$9 | ﹤0.01% | 6065 |
|
|
2023
Q4 | $102K | Buy |
59,277
+14,824
| +33% | +$26.4K | ﹤0.01% | 5937 |
|
|
2023
Q3 | $83.1K | Hold |
44,453
| – | – | ﹤0.01% | 5971 |
|
|
2023
Q2 | $106K | Sell |
44,453
-241
| -0.5% | -$586 | ﹤0.01% | 5928 |
|
|
2023
Q1 | $88.9K | Hold |
44,694
| – | – | ﹤0.01% | 6055 |
|
|
2022
Q4 | $87.2K | Buy |
44,694
+3
| +0% | +$8 | ﹤0.01% | 6045 |
|
|
2022
Q3 | $156K | Hold |
44,691
| – | – | ﹤0.01% | 5846 |
|
|
2022
Q2 | $220K | Sell |
44,691
-14,976
| -25% | -$79.8K | ﹤0.01% | 5851 |
|
|
2022
Q1 | $394K | Buy |
59,667
+166
| +0.3% | +$1.1K | ﹤0.01% | 5544 |
|
|
2021
Q4 | $464K | Hold |
59,501
| – | – | ﹤0.01% | 5597 |
|
|
2021
Q3 | $750K | Hold |
59,501
| – | – | ﹤0.01% | 5245 |
|
|
2021
Q2 | $893K | Sell |
59,501
-583
| -1% | -$8.86K | ﹤0.01% | 5145 |
|
|
2021
Q1 | $1M | Buy |
60,084
+647
| +1% | +$13.1K | ﹤0.01% | 4732 |
|
|
2020
Q4 | $970K | Hold |
59,437
| – | – | ﹤0.01% | 4689 |
|
|
2020
Q3 | $663K | Sell |
59,437
-125
| -0.2% | -$2.28K | ﹤0.01% | 4482 |
|
|
2020
Q2 | $1.09M | Hold |
59,562
| – | – | ﹤0.01% | 4107 |
|
|
2020
Q1 | $507K | Buy |
59,562
+167
| +0.3% | +$1.57K | ﹤0.01% | 4358 |
|
|
2019
Q4 | $353K | Buy |
59,395
+59,103
| +20,241% | +$590K | ﹤0.01% | 5121 |
|
|
2019
Q3 | $7K | Hold |
292
| – | – | ﹤0.01% | 6291 |
|
|
2019
Q2 | $8K | Sell |
292
-1,000
| -77% | -$29.7K | ﹤0.01% | 6185 |
|
|
2019
Q1 | $42K | Sell |
1,292
-375
| -22% | -$13.7K | ﹤0.01% | 5740 |
|
|
2018
Q4 | $72K | Buy |
1,667
+331
| +25% | +$10.9K | ﹤0.01% | 5661 |
|
|
2018
Q3 | $40K | Buy |
1,336
+1,333
| +44,433% | +$59.6K | ﹤0.01% | 5932 |
|
|
2018
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 6669 |
|
|
2018
Q1 | $0 | Buy |
+3
| New | +$187 | ﹤0.01% | 6620 |
|
Other funds holding COCP
XT
Morgan Stanley's COCP Position: Q2 2026 in Review
Morgan Stanley reduced its Cocrystal Pharma (COCP) stake by 8.1% in Q2 2026, selling an estimated $95 and leaving 871 shares worth $915. The position accounts for ﹤0.01% of the portfolio, ranked #7524.
Morgan Stanley first reported a position in COCP in Q1 2018 and has held it in 34 quarters since. The position peaked at $1.09M in Q2 2020. 27 funds tracked by Wall St. Rank hold COCP as of Q2 2026.
- Morgan Stanley held 871 shares of Cocrystal Pharma worth $915 as of Q2 2026.
- Morgan Stanley sold 77 Cocrystal Pharma shares in Q2 2026, an estimated $95.
- Cocrystal Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7524 holding.
- Morgan Stanley first reported a position in Cocrystal Pharma in Q1 2018 and has held it in 34 quarters since.
- Morgan Stanley's Cocrystal Pharma position peaked at $1.09M in Q2 2020.
- 27 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.